Date: Nov. 11, 2023
Time: 1:00-2:00 pm ET
Format: Poster presentation: CM-101, a CCL24 neutralizing antibody, showed improvements in inflammatory, fibrotic, and metabolic pathways in patients with NASH: Proteomics analysis of a Phase 2a study
Presenter: Matt Frankel, MD, Chief Medical Officer & Vice President of Drug Development, Chemomab Therapeutics
Authors: Revital Aricha, Tom Snir, Ilan Vaknin, John Lawler, Adi Mor, Matt Frankel
Session: Poster session Hall C – 2^nd level
Information: The Liver Meeting | AASLD